Skip to content
Products & Services · Product revenues, net

JOURNAVX — Product revenues, net

Vertex Pharmaceuticals JOURNAVX — Product revenues, net increased by 8.6% to $29M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2130.8%, from $1.3M to $29M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2024
Last reportedQ1 2026May 5, 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates successful market adoption, effective commercialization, and growing patient demand for the therapy, while a decrease may signal competitive pressure, market saturation, or challenges in patient access.

Detailed definition

This metric represents the total net sales generated from the JOURNAVX product line after accounting for returns, rebate...

Peer comparison

Comparable to product-specific net revenue lines reported by other biotechnology and pharmaceutical companies for their key commercialized assets.

Metric ID: vrtx_segment_journavx_product_revenues_net

Historical Data

9 periods
 Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0$0$0$0$1.3M$12M$19.6M$26.7M$29M
QoQ Change+823.1%+63.3%+36.2%+8.6%
YoY Change>999%
Range$0$29M
Avg YoY Growth>999%
Median YoY Growth>999%
Current Streak4+ quarters growth

Frequently Asked Questions

What is Vertex Pharmaceuticals's journavx — product revenues, net?
Vertex Pharmaceuticals (VRTX) reported journavx — product revenues, net of $29M in Q1 2026.
How has Vertex Pharmaceuticals's journavx — product revenues, net changed year-over-year?
Vertex Pharmaceuticals's journavx — product revenues, net increased by 2130.8% year-over-year, from $1.3M to $29M.
What does journavx — product revenues, net mean?
The total net sales revenue generated specifically from the JOURNAVX product.